Open AccessInterim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan
Author(s) -
Haruko Sugamori,
Takumi Lee,
Takeshi Mitomi,
Chika Yamagishi
Publication year - 2022
Publication title -
japanese journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.768
H-Index - 85
eISSN - 1465-3621
pISSN - 0368-2811
DOI - 10.1093/jjco/hyac069
Subject(s) - medicine , discontinuation , adverse effect , adverse drug reaction , surgery , gastroenterology , drug , pharmacology
Gilteritinib received approval for the treatment of FLT3-mutated relapsed or refractory acute myeloid leukemia in Japan in 2018. In accordance with regulatory requirements, we conducted a multicenter, observational surveillance of gilteritinib use in Japan.